![]() |
市场调查报告书
商品编码
1497580
再生医学中的人工智慧市场:按技术、产品、应用和最终用户划分 - 2024-2030 年全球预测Artificial Intelligence in Regenerative Medicine Market by Technology (Computer Vision, Context-Aware Computing, Machine Learning), Offering (Hardware, Services, Software), Application, End-User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年人工智慧再生医学市场规模为5,963万美元,预计2024年将达7,238万美元,2030年将达到2.4063亿美元,复合年增长率为22.05%。
人工智慧 (AI) 在再生医学中变得越来越重要,因为它是一种修復、替换和再生人体内受损或失去的组织和器官的多学科方法。人工智慧技术正在应用于再生医学的各个方面,以加速研究、增强患者治疗并改善治疗结果。再生医学市场中的人工智慧包括将机器学习演算法、深度学习系统、自然语言处理工具和机器人等人工智慧技术整合到干细胞疗法、组织工程、免疫疗法和基因编辑技术中。公共和私营部门对研发活动的资金增加正在加速人工智慧等先进技术的采用。此外,癌症和心血管疾病等慢性疾病的盛行率不断上升,需要创新的治疗方法,而这些方法只能透过人工智慧驱动的再生医学提供的突破性解决方案来解决,需求不断增加,市场成长进一步加快。然而,用于训练人工智慧演算法的患者资讯的敏感性引发了资料隐私问题,而人工智慧系统使用的复杂演算法阻碍了市场的采用。个人化治疗的出现和次世代定序(NGS)技术的进步正在产生大量需要先进分析技术的资料,为人工智慧在再生医学中的应用创造了新的机会。
主要市场统计 | |
---|---|
基准年[2023] | 5963万美元 |
预测年份 [2024] | 7238万美元 |
预测年份 [2030] | 24063万美元 |
复合年增长率(%) | 22.05% |
区域洞察
由于拥有大量投资、合作伙伴关係以及持续关注市场创新的主要市场参与者,美洲在再生医学人工智慧市场中占据关键地位。此外,政府的主导正在汇集各领域的研究人员,专注于整合人工智慧技术,开发器官再生和修復的新治疗方法。在欧盟 (EU),地平线 2020 等资助计画正在分配大量资源来推进以人工智慧为基础的再生医学计划。政府推出了几个计划,使用机器学习演算法来绘製人类的每种细胞类型,进一步刺激了该地区的市场采用。在政府大量投资的支持下,亚太地区正在快速推动以人工智慧为基础的再生医学。主要公司正在建立专门的医疗保健部门,将人工智慧技术应用于医疗问题,包括再生疗法。政府也启动了战略倡议,开发再生医学人工智慧技术,以支持医疗保健和生物技术等产业,进一步加速该地区的市场采用。
FPNV定位矩阵
FPNV 定位矩阵对于评估再生医学市场人工智慧供应商的市场定位至关重要。此矩阵提供了对供应商的全面评估,并检查了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对再生医学市场人工智慧供应商的现状进行深入而详细的评估。对供应商贡献的彻底比较和分析可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外,该分析还提供了对该行业竞争力的宝贵见解,包括研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对再生医学市场人工智慧当前地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[185 Pages Report] The Artificial Intelligence in Regenerative Medicine Market size was estimated at USD 59.63 million in 2023 and expected to reach USD 72.38 million in 2024, at a CAGR 22.05% to reach USD 240.63 million by 2030.
Artificial intelligence (AI) is increasingly important in regenerative medicine as it is a multidisciplinary approach to repairing, replacing, or regenerating damaged or lost tissues and organs within the human body. AI technologies are applied to various aspects of regenerative medicine to accelerate research, enhance patient care, and improve treatment outcomes. The AI in the regenerative medicine market encompasses integrating AI technologies such as machine learning algorithms, deep learning systems, natural language processing tools, and robotics with stem cell therapy, tissue engineering, immunotherapies, and gene editing techniques. Increased funding for research & development activities in both public and private sectors has accelerated the adoption of advanced technologies such as AI. Additionally, the rising prevalence of chronic conditions such as cancer and cardiovascular diseases has increased demand for innovative treatment approaches that can only be met through groundbreaking solutions provided by AI-enabled regenerative medicine, further increasing market growth. However, data privacy concerns arise due to the sensitive nature of patient information used for training AI algorithms, and the complex algorithms used by AI systems hamper market adoption. The advent of personalized therapy and advances in next-generation sequencing (NGS) technologies have generated vast amounts of data requiring sophisticated analysis methods; this poses yet another opportunity for AI's application within the regenerative medicine landscape.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 59.63 million |
Estimated Year [2024] | USD 72.38 million |
Forecast Year [2030] | USD 240.63 million |
CAGR (%) | 22.05% |
Regional Insights
The Americas hold a significant landscape in the artificial intelligence in regenerative medicine market owing to significant investments and partnerships and the presence of key market players continuously focusing on innovations in the market. Additionally, the government initiative brings together researchers from various fields who focus on integrating AI technologies to develop novel therapeutic approaches for organ regeneration and repair. In the European Union, funding programs such as Horizon 2020 have allocated substantial resources to advance AI-based regenerative medicine projects. The government has launched several projects to map every human cell type using machine learning algorithms, further fueling the region's market adoption. APAC region is rapidly advancing in AI-based regenerative medicine, backed by significant government investments. Leading companies have established dedicated healthcare units that apply AI technologies to medical issues, including regenerative therapies. The government has also launched strategic initiatives to develop AI technologies for regenerative medicine to support industries such as healthcare and biotechnology, further fueling market adoption in the region.
Market Insights
The market dynamics represent an ever-changing landscape of the Artificial Intelligence in Regenerative Medicine Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Artificial Intelligence in Regenerative Medicine Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Artificial Intelligence in Regenerative Medicine Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Axolotl Biologix and Carmell Therapeutics Enter Merger Deal
Axolotl and Carmell entered into a merger agreement to advance Artificial Intelligence (AI) in Regenerative Medicine. This merger will create a company with the largest AI platform for optimizing human tissue development. Both companies will share their AI, data science, and 3D organ fabrication expertise. Through this collaboration, they aim to facilitate innovation in cellular therapies and drug development, strongly focusing on improving patient outcomes. [Published On: 2023-09-13]
Epredia and Aiforia Join RegenMed Hub Innovation Accelerator, Expanding PHC Group Presence in Regenerative Medicine Partnership Will Pave the Way for New RegenMed Clinical Trials Catalyst Program
PHC Group announced to expand its presence in regenerative medicine by joining the RegeneratOR Innovation Accelerator. The combination of diagnostic microscopic imaging and AI has created a bridge between drug discovery, translational, and clinical research programs, enabling a better understanding of disease states. [Published On: 2023-01-19]
Wipro and Pandorum Partner to Accelerate Regenerative Medicine with Artificial Intelligence
Wipro entered into a strategic partnership with Pandorum Technologies, aiming to expedite advancements in regenerative medicine through AI. This collaboration between the two companies involves the development of therapies and diagnostics, leveraging predictive analytics and multi-modal data integration. By combining Pandorum's expertise in tissue engineering technology with Wipro's extensive experience in building AI-driven medical solutions, the partnership seeks to accelerate the progress of innovative regenerative therapies. [Published On: 2022-03-11]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Artificial Intelligence in Regenerative Medicine Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Artificial Intelligence in Regenerative Medicine Market, highlighting leading vendors and their innovative profiles. These include Cognetivity Ltd., F. Hoffmann-La Roche Ltd., Intel Corporation, Medtronic PLC, Merck KGaA, Microsoft Corporation, NANO-X IMAGING LTD., Novo Nordisk A/S, NVIDIA Corporation, Sanofi SA, Tempus Labs, Inc., and Wipro Limited.
Market Segmentation & Coverage